Triple Negative Breast Neoplasms: all 1,163 studies

Page 12 of 12. Open to participants first (447), then studies with results posted, then the rest; newest registration first within each.

• A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced CancerWithdrawnNCT02038699Phase 1/2
• A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast CancerCompletedNCT02032277Phase 3
• Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid TumorsCompletedNCT02014337Phase 1
• Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast CancerStatus unknownNCT02012634
• RX-5902 Treatment of Subjects With Triple Negative Breast CancerTerminatedNCT02003092Phase 1/2
• Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negative Breast Cancer for Neoadjuvant ChemotherapyCompletedNCT02001519Phase 2
• LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or PembrolizumabCompletedNCT01986426Phase 1
• A Safety Study of SGN-LIV1A in Breast Cancer PatientsCompletedNCT01969643Phase 1
• Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast CancerCompletedNCT01969032Phase 2
• Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer TherapyTerminatedNCT01957514
• Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)WithdrawnNCT01953536Phase 2
• Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid TumorsWithdrawnNCT01936961Not applicable
• AZD8186 First Time In Patient Ascending Dose StudyCompletedNCT01884285Phase 1
• cMet CAR RNA T Cells Targeting Breast CancerCompletedNCT01837602Phase 1
• Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast CancerCompletedNCT01815242Phase 2
• A Phase III Trial of Carboplatin as Adjuvant Chemotherapy in Triple Negative Breast CancerStatus unknownNCT01752686Phase 3
• Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast CancerWithdrawnNCT01695057Not applicable
• An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast CancerCompletedNCT01677455Phase 2
• Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast CancerCompletedNCT01676753Phase 1
• Cisplatin + RT for Triple Negative Breast CancerCompletedNCT01674842Phase 1
• BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based ChemotherapyCompletedNCT01672671Phase 2
• Study of Erlotinib and Metformin in Triple Negative Breast CancerCompletedNCT01650506Phase 1
• Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast CancerStatus unknownNCT01642771Phase 3
• Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBCCompletedNCT01639248Phase 2
• Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast CancerCompletedNCT01624441Phase 1
• Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian CancerCompletedNCT01623349Phase 1
• An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid TumorsCompletedNCT01618136Phase 1/2
• Predictors of Response to Neoadjuvant Docetaxel-Carboplatin Chemotherapy for Patients With Stage II and III Triple Negative Breast CancerActive, not recruitingNCT01560663
• Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a Prospective TrialStatus unknownNCT01528826Phase 2
• Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary TreatmentCompletedNCT01520389Phase 1
• Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast CancerStatus unknownNCT01514565
• Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212CompletedNCT01467310Early Phase 1
• Triple Negative Breast Cancer: Study of Molecular and Genetic FactorsStatus unknownNCT01434420Not applicable
• Study of Chemotherapy With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer PatientsCompletedNCT01395056
• Safety Study of MGA271 in Refractory CancerCompletedNCT01391143Phase 1
• The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBCStatus unknownNCT01378533Phase 3
• Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer PatientsStatus unknownNCT01372579Phase 2
• A Study of LGK974 in Patients With Malignancies Dependent on Wnt LigandsCompletedNCT01351103Phase 1
• Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)WithdrawnNCT01333423Phase 1
• A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and CarboplatinTerminatedNCT01333137Phase 1
• Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By SurgeryWithdrawnNCT01292083Not applicable
• Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Paclitaxel in Triple Negative Breast Cancer (TNBC)CompletedNCT01287624Phase 3
• Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer PatientsCompletedNCT01276899
• Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast CancerStatus unknownNCT01276769Phase 2
• Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast CancerActive, not recruitingNCT01251874Phase 1
• Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast CancerCompletedNCT01238952Phase 1
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast CancerTerminatedNCT01238133Phase 1
• Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer PatientsCompletedNCT01232062
• Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)CompletedNCT01216111Phase 3
• Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer PatientsCompletedNCT01204125Phase 2
• Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast CancerCompletedNCT01186991Phase 2
• Study of Apatinib in Metastatic Triple-Negative Breast Cancer PatientsCompletedNCT01176669Phase 2
• A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain MetastasisCompletedNCT01173497Phase 2
• Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast CancerCompletedNCT01150513Phase 2/3
• Triple Negative Breast Cancer Biomarker StudyCompletedNCT01111175
• Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast CancerCompletedNCT01104259Phase 1
• Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast CancerCompletedNCT01045304Phase 2
• Study of Temsirolimus, Erlotinib and Cisplatin in Solid TumorsCompletedNCT00998036Phase 1
• MUC1 Vaccine for Triple-negative Breast CancerCompletedNCT00986609Early Phase 1
• A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast CancerCompletedNCT00951054Phase 2
• A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast CancerCompletedNCT00813956Phase 2
• Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast CancerCompletedNCT00707707Phase 1
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1

← Triple Negative Breast Neoplasms overview